← Leaderboards
Vittorio Cristini
University Of Texas Hlth Sci Ctr Houston
$4,662,941
Attributed
$8,781,919
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2009–22$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$11,477,305 · 6
By mechanism
R01$5,777,012 · 2
U54$5,700,293 · 4
Top collaborators
- Wadih Arap5 shared
- C Jeffrey Brinker5 shared
- George A. Calin5 shared
- Bulent Ozpolat5 shared
- Renata Pasqualini5 shared
- Mauro Ferrari1 shared
- Gabriel Lopez-Berestein1 shared
- Anil K Sood1 shared
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Hulin Wu$27,255,941
- Paolo Decuzzi$1,404,711
Others in their field
Top investigators on “Mathematical Model”
- Deborah J Donnell · Fred Hutchinson Cancer Center$140,607,304
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,263,426
- Myron S Cohen · Family Health International$91,263,426
- Gregory D Peterson · University Of Tennessee Knoxville$84,527,696
- Robert A Kamphaus · University Of Washington$83,310,874
- Anders Ryd · Cornell University$79,389,944
Research focus
Mathematical ModelTumor GrowthMulti-Scale ModelingTumorCellsDesignTissuesIn VitroHybridsMolecularIn VivoNanomedicineResponseMacrophageComputer SimulationSimulationInnovationAntineoplastic AgentsPropertyGenerationsEngineeringMathematicsEnvironmentMalignant Neoplasms
Grant awards (23)
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$629,467
R01 · FY2022 · CA
miR-155 targeted therapeutics for precision medicine in lung cancer$501,986
R01 · FY2022 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$642,358
R01 · FY2021 · CA
miR-155 targeted therapeutics for precision medicine in lung cancer$512,229
R01 · FY2021 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$642,804
R01 · FY2020 · CA
miR-155 targeted therapeutics for precision medicine in lung cancer$512,231
R01 · FY2020 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$623,916
R01 · FY2019 · CA
miR-155 targeted therapeutics for precision medicine in lung cancer$502,255
R01 · FY2019 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$673,092
R01 · FY2018 · CA
miR-155 targeted therapeutics for precision medicine in lung cancer$536,674
R01 · FY2018 · CA
Texas Center for Cancer Nanomedicine$2,695,386
U54 · FY2014 · CA · contact PI
Multi-Scale Bio-Simulations$60,711
U54 · FY2014 · CA · contact PI
Multi-Scale Cancer Modeling: From Cell Phenotypes to Cancer Spread and Response$350,177
U54 · FY2013 · CA · contact PI
Multi-Scale Bio-Simulations$350,120
U54 · FY2013 · CA · contact PI
Multi-Scale Cancer Modeling: From Cell Phenotypes to Cancer Spread and Response$364,580
U54 · FY2012 · CA · contact PI
Multi-Scale Bio-Simulations$192,018
U54 · FY2012 · CA · contact PI
Multi-Scale Cancer Modeling: From Cell Phenotypes to Cancer Spread and Response$363,394
U54 · FY2011 · CA · contact PI
Multi-Scale Bio-Simulations$140,080
U54 · FY2011 · CA · contact PI
Multi-Scale Cancer Modeling: From Cell Phenotypes to Cancer Spread and Response$375,857
U54 · FY2010 · CA · contact PI
Multi-Scale Bio-Simulations$147,594
U54 · FY2010 · CA · contact PI
Multi-Scale Bio-Simulations$146,481
U54 · FY2010 · CA · contact PI
Multi-Scale Cancer Modeling: From Cell Phenotypes to Cancer Spread and Response$368,469
U54 · FY2009 · CA · contact PI
Multi-Scale Bio-Simulations$145,426
U54 · FY2009 · CA · contact PI